John Z Zhao1, Scott Hadley1, Emerson Floyd1, Brandon E Earp1, Philip E Blazar2. 1. Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA. 2. Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA. Electronic address: pblazar@partners.org.
Abstract
PURPOSE: The U.S. Food and Drug Administration approved the use of collagenase Clostridium histolyticum (CCH) in the United States in February 2010. This study addresses the impact of that approval on the number of Dupuytren contracture (DC) encounters and treatment patterns in the United States. METHODS: Using the Intercontinental Marketing Services Health Office-Based Medical Claims database, we identified the monthly number of DC encounters and DC procedures between January 2007 and December 2013. Collagenase Clostridium histolyticum usage data from March 2010 to December 2013 was derived from the U.S. CCH manufacturer's data warehouse. Using the combined data, the yearly increasing trends in DC encounters and treatment volume were compared before and after the introduction of CCH. Time trends in the relative procedure frequencies were then examined. Finally, the presence of seasonal variation was tested for in each treatment type. RESULTS: Dupuytren contracture encounters increased on average by 19,015 per year between 2007 and 2009, whereas between 2011 and 2013, DC encounters increased on average by 34,940 per year. In terms of absolute procedure counts, the surgery trend line began decreasing in 2010 with the release of CCH. Meanwhile, CCH continuously increased between 2010 and 2013, and needle aponeurotomy (NA) remained relatively stable. By the year 2013, minimally invasive techniques (NA and CCH) comprised 39% of all treatment, compared with only 14% in 2007. Lastly, there was a statistically significant seasonal increase in the number of surgical procedures during the wintertime but no seasonal variation in NA or CCH. CONCLUSIONS: After the introduction of CCH, the number of Dupuytren encounters increased at a greater annual rate. The introduction and growth of CCH coincided with a decrease in surgery. The number of NA procedures remained steady throughout the study period. The number of open surgery cases followed a predictable seasonal variation with more procedures during the winter months, but this seasonal variation was not seen with less invasive techniques. TYPE OF STUDY/LEVEL OF EVIDENCE: Economic/Decision Analysis II.
PURPOSE: The U.S. Food and Drug Administration approved the use of collagenase Clostridium histolyticum (CCH) in the United States in February 2010. This study addresses the impact of that approval on the number of Dupuytren contracture (DC) encounters and treatment patterns in the United States. METHODS: Using the Intercontinental Marketing Services Health Office-Based Medical Claims database, we identified the monthly number of DC encounters and DC procedures between January 2007 and December 2013. Collagenase Clostridium histolyticum usage data from March 2010 to December 2013 was derived from the U.S. CCH manufacturer's data warehouse. Using the combined data, the yearly increasing trends in DC encounters and treatment volume were compared before and after the introduction of CCH. Time trends in the relative procedure frequencies were then examined. Finally, the presence of seasonal variation was tested for in each treatment type. RESULTS: Dupuytren contracture encounters increased on average by 19,015 per year between 2007 and 2009, whereas between 2011 and 2013, DC encounters increased on average by 34,940 per year. In terms of absolute procedure counts, the surgery trend line began decreasing in 2010 with the release of CCH. Meanwhile, CCH continuously increased between 2010 and 2013, and needle aponeurotomy (NA) remained relatively stable. By the year 2013, minimally invasive techniques (NA and CCH) comprised 39% of all treatment, compared with only 14% in 2007. Lastly, there was a statistically significant seasonal increase in the number of surgical procedures during the wintertime but no seasonal variation in NA or CCH. CONCLUSIONS: After the introduction of CCH, the number of Dupuytren encounters increased at a greater annual rate. The introduction and growth of CCH coincided with a decrease in surgery. The number of NA procedures remained steady throughout the study period. The number of open surgery cases followed a predictable seasonal variation with more procedures during the winter months, but this seasonal variation was not seen with less invasive techniques. TYPE OF STUDY/LEVEL OF EVIDENCE: Economic/Decision Analysis II.
Authors: Mikko P Räisänen; Teemu Karjalainen; Harry Göransson; Aleksi Reito; Hannu Kautiainen; Antti Malmivaara; Olli V Leppänen Journal: BMJ Open Date: 2018-03-28 Impact factor: 2.692
Authors: Jagdeep Nanchahal; Catherine Ball; Dominique Davidson; Lynn Williams; William Sones; Fiona E McCann; Marisa Cabrita; Jennifer Swettenham; Neil J Cahoon; Bethan Copsey; E Anne Francis; Peter C Taylor; Joanna Black; Vicki S Barber; Susan Dutton; Marc Feldmann; Sarah E Lamb Journal: EBioMedicine Date: 2018-07-06 Impact factor: 8.143
Authors: Jagdeep Nanchahal; Catherine Ball; Jennifer Swettenham; Susan Dutton; Vicki Barber; Joanna Black; Bethan Copsey; Melina Dritsaki; Peter Taylor; Alastair Gray; Marc Feldmann; Sarah Lamb Journal: Wellcome Open Res Date: 2017-06-06